Oxford Immunotec Global PLC (OXFD)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

94C INNOVATION DRIVE ABINGDON, UNITED KINGDOM OX14 4RZ

Oxford Immunotec Global PLC is a medical diagnostics company developing new tests for various diseases based on its, patented T cell measurement technology.

Data as of 2020-11-22
Market Cap355.677 Million Shares Outstanding25.962 Million Avg 30-day Volume138.373 Thousand
P/E Ratio-20.4 Dividend Yield EPS-0.67
Price/Sales6.208 Price cash flow ratio44.6 Price free cash flow ratio-20.3
Book Value7.37 Price to Tangible Book1.88 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.186518
BETA1.28006 52-week High/Low17.77 / 8.37 Stddev0.124902
View SEC Filings from OXFD instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 4 5 -20.0% 4 (0.26%) 4 (0.26%) 0.0%
Funds Holding: 71 66 7.58% 35 (2.3%) 34 (2.21%) 2.94%
13F shares: 23.917 Million 23.398 Million 2.22% 20.727 Million 19.932 Million 3.99%
% Ownership 92.1475 90.147 2.22% 79.8552 76.7926 3.99%
New Positions: 11 12 -8.33% 6 5 20.0%
Increased Positions 21 26 -19.23% 11 16 -31.25%
Closed Positions 6 12 -50.0% 5 5 0.0%
Reduced Positions 24 19 26.32% 11 8 37.5%
Total Calls 10 10 0.0%
Total Puts 0 0
PUT/CALL Ratio 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OXFD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OXFD BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SANDBERG RICHARD A

  • Director
4,081 2020-06-24 1

RANDALL PATRICIA

  • Director
27,805 2020-06-24 2

ROSENMAN HERM

  • Director
4,081 2020-06-24 1

TOBIN JAMES R

  • Director
4,081 2020-06-24 1

ANDREWS RONALD ASBURY

  • Director
4,081 2020-06-24 1

WALTON ANDREW SCOTT

  • Director
4,081 2020-06-24 1

BALTHROP PATRICK J

  • Director
4,081 2020-06-24 3

KLAUSNER MARK R.

  • Director
4,081 2020-06-24 1

WRIGHTON-SMITH PETER CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
400,225 2020-05-08 2

LINN STEFAN C CHIEF OPERATING OFFICER

  • Officer
96,301 2020-03-11 1

MCLAUGHLIN MATTHEW T E CHIEF FINANCIAL OFFICER

  • Officer
61,407 2020-03-11 1

KIDD JANET LOUISE GENERAL COUNSEL

  • Officer
11,207 2019-11-18 0

KEILEY ELIZABETH M SVP & GENERAL COUNSEL

  • Officer
26,928 2019-03-04 0

ALTIERI RICHARD M. CHIEF FINANCIAL OFFICER

  • Officer
207,965 2019-01-01 0

WENSTRUP RICHARD CHIEF MEDICAL OFFICER

  • Officer
22,992 2018-03-15 0

EDWARDSON PETER CHIEF OPERATIONS OFFICER

  • Officer
92,905 2017-08-15 0

SPOTTS STEPHEN L

  • Director
0 2017-06-06 0

SCHROEDER JEFF R. CHIEF COMMERCIAL OFFICER

  • Officer
127,147 2017-05-08 0

CLARUS LIFESCIENCES I, L.P.

CLARUS VENTURES I MANAGEMENT, L.P.

CLARUS VENTURES I, LLC

GALAKATOS NICHOLAS

HENNER DENNIS

LIPTAK ROBERT

SIMON NICHOLAS

WHEELER KURT

  • 10% Owner
No longer subject to file 2015-06-15 0

NEW LEAF VENTURES II, L.P.

NEW LEAF VENTURE ASSOCIATES II, L.P.

NEW LEAF VENTURE MANAGEMENT II, L.L.C.

CHAMBON PHILIPPE O.

NIEDEL JAMES

HUNT RONALD

DELAGARDELLE JEANI

RATCLIFFE LIAM

  • Director
  • FORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNERFORMER 10% BENEFICIAL OWNER
No longer subject to file 2013-11-27 0

PITCHFORD NIGEL A.

  • Director
833,448 2013-11-21 0

LATHI VIJAY K

  • Director
  • 10% Owner
1,377,497 2013-11-21 0

STEINMETZ MICHAEL

  • Director
  • 10% Owner
2,579,062 2013-11-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments